Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy

Core Insights - Artelo Biosciences, Inc. announced new research on ART26.12, a novel FABP5 inhibitor aimed at treating Oxaliplatin-Induced Peripheral Neuropathy (OIPN) [1][2] - The global neuropathic pain market is valued at approximately $7.6 billion, indicating a significant demand for innovative non-opioid pain relief therapies [3] Company Overview - Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing treatments that modulate lipid-signaling pathways for conditions such as cancer, pain, and neurological disorders [5] - The company is advancing a portfolio of therapeutics designed to address unmet medical needs across various diseases, including cancer and neuropathic pain [5] Product Development - ART26.12 has demonstrated minimal off-target effects and high oral bioavailability in pre-clinical safety studies, with a NOAEL of 1000 mg/kg/day [3] - The company plans to file an Investigational New Drug (IND) application for ART26.12 in the first half of 2024 following a positive pre-IND meeting with the FDA [3] Market Context - Chemotherapy-induced peripheral neuropathy (CIPN) is a significant challenge in cancer treatment, affecting up to 98% of patients treated with Oxaliplatin, often leading to dose reductions or treatment cessation [2][6] - Approximately 30% of patients may experience chronic CIPN lasting a year or more after chemotherapy [6]